Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
October 29, 2020 07:55 ET
|
Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development...
Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable
October 26, 2020 07:55 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
September 22, 2020 07:30 ET
|
Vaccinex, Inc.
Key cognitive endpoints trending towards but did not reach statistical significance in early manifest population. Overall study does not meet pre-specified co-primary endpoints Results support...
Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer
August 27, 2020 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease...
Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series
June 09, 2020 08:00 ET
|
Vaccinex, Inc.
Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session ROCHESTER, N.Y., June 09,...
Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020 08:45 ET
|
Vaccinex, Inc.
Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to expand pepinemab development to include Alzheimer’s disease ROCHESTER, N.Y., May 14, 2020 ...
Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs
March 31, 2020 07:55 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 31, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation
December 10, 2019 08:02 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer,...
Vaccinex Announces Award Notice from the Alzheimer’s Association 2020 Part the Cloud Program
November 14, 2019 07:55 ET
|
Vaccinex, Inc.
Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease ...
Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)
April 24, 2017 10:28 ET
|
Vaccinex, Inc.
- Subjects were rapidly recruited and consistently retained and dosed - - No concerning safety signals were identified - – Imaging data from SIGNAL Cohort A indicate treatment effect on...